Results 131 to 140 of about 101,476 (335)

Canine lymphoma: a retrospective study (2009-2010) [PDF]

, 2012
This study reviews the medical records of 56 dogs diagnosed with lymphoma based on the cytological and/or histological results between January 1, 2009 and December 31, 2010.
Daminet, Sylvie, Mortier, Femke, Van de Maele, Isabel, Vandenabeele, Sophie   +3 more
core   +1 more source

Large‐cell transformation of mycosis fungoides: Patterns of care and patient outcomes

British Journal of Haematology, EarlyView.
Large‐cell transformation of mycosis fungoides is rare with poor prognosis. Presenting over 20 years of data, this retrospective study of 83 patients demonstrated a median overall survival (mOS) of 3.5 years. However, prognostic differences in three clinical subgroups were suggested: unifocal, multifocal, extra‐cutaneous (mOS: 4.6, 2.5, 1.1 years ...
Philippa Johnstone, Martin Higgins, H. Miles Prince, Stephen Lade, Chris McCormack, Carrie van der Weyden, Friyana Bhabha, Odette Buelens, Piers Blombery, Belinda A. Campbell   +9 more
wiley   +1 more source

Clinical periodontal diagnosis

Periodontology 2000, EarlyView., 2023
Abstract Periodontal diseases include pathological conditions elicited by the presence of bacterial biofilms leading to a host response. In the diagnostic process, clinical signs such as bleeding on probing, development of periodontal pockets and gingival recessions, furcation involvement and presence of radiographic bone loss should be assessed prior ...
Giovanni E. Salvi, Andrea Roccuzzo, Jean‐Claude Imber, Alexandra Stähli, Björn Klinge, Niklaus P. Lang   +5 more
wiley   +1 more source

The role of ¹⁸F-FDG PET/CT in primary cutaneous lymphoma: an educational review. [PDF]

Ann Nucl Med, 2023
McDonald EO, Amanullah AA, Park PSU, Song W, Werner TJ, Alavi A, Revheim ME.   +6 more
europepmc   +1 more source

Secondary malignancies after chronic myeloid leukaemia upon TKI treatment: Population trends and outcomes

British Journal of Haematology, EarlyView.
A retrospective study from 11 institutions was performed in 139 chronic myeloid leukaemia (CML) patients with secondary malignancies. The median ages at diagnosis of CML and secondary malignancy were 51 years (range, 13–88 years) and 53 years (range, 18–91 years). After a median follow‐up of 85 months, the median time from diagnosis of CML to secondary
Yingling Zu, Xipeng Yue, Xinrong Zhan, Xiaojuan Liu, Hongxia Ma, Fuli Qin, Lijuan Duan, Hongmian Zhao, Yan Zhang, Shiqiang He, Huifang Zhao, Chunlei Zhang, Xiangke Xin, Wenli Zhang, Yongping Song, Bingcheng Liu, Weiming Li, Yanli Zhang   +17 more
wiley   +1 more source

Acute Generalized Exanthematous Pustulosis in a Setting of Cutaneous Lymphoma. [PDF]

Cureus, 2022
Budh DP, Hawa S, Rios D, Chilakala A, Paniagua JA.   +4 more
europepmc   +1 more source

The impact of Foxp3+ regulatory T‐cells on CD8+ T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have been a breakthrough in cancer therapy, inducing durable remissions in responding patients. However, they are associated with variable outcomes, spanning from disease hyperprogression to complete responses with the onset of immune‐related adverse events.
Mikhaël Attias, Ciriaco A. Piccirillo
wiley   +1 more source

Dermoscopy in the diagnosis of cutaneous lymphoma (Review). [PDF]

Exp Ther Med, 2022
Ungureanu L, Vasilovici A, Șenilă SC, Cosgarea I, Boda D.   +4 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

hMZF-2, the Elusive Transcription Factor

Frontiers in Genetics, 2020
Alain Chebly, Alain Chebly, Jean-Marie Peloponese, Evelyne Ségal-Bendirdjian, Jean-Philippe Merlio, Jean-Philippe Merlio, Roland Tomb, Roland Tomb, Edith Chevret   +8 more
doaj   +1 more source